Review
CD4+ T lymphocytes: a critical component of antitumor immunity
Affiliations
- PMID: 16193641
Item in Clipboard
Review
CD4+ T lymphocytes: a critical component of antitumor immunity
Cancer Invest.
2005.
Abstract
Both prophylactic and therapeutic vaccines targeting a wide variety of cancers are being developed. Because of the potency of cell-mediated immunity, many vaccine strategies are focused on activating tumor-specific cytotoxic CD8+ T lymphocytes. CD4+ T lymphocytes are a key element in optimal activation of CD8+ T cells and in the maintenance of immune memory, and therefore their activation is critical for cancer vaccine efficacy. This article reviews the mechanisms by which CD4+ T cells facilitate tumor immunity and the vaccine strategies that enhance CD4+ T cell activity.
Similar articles
-
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880. Clin Cancer Res. 2008. PMID: 18172269 Clinical Trial.
-
Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.J Leukoc Biol. 2007 Oct;82(4):829-38. doi: 10.1189/jlb.0407249. Epub 2007 Jul 11. J Leukoc Biol. 2007. PMID: 17626150
-
Immune regulation in tumor-bearing hosts.Curr Opin Immunol. 2006 Apr;18(2):214-9. doi: 10.1016/j.coi.2006.01.010. Epub 2006 Feb 7. Curr Opin Immunol. 2006. PMID: 16464567 Review.
-
alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.Hum Immunol. 2007 May;68(5):334-41. doi: 10.1016/j.humimm.2007.01.008. Epub 2007 Feb 21. Hum Immunol. 2007. PMID: 17462500
-
Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design.Expert Rev Vaccines. 2005 Oct;4(5):711-23. doi: 10.1586/14760584.4.5.711. Expert Rev Vaccines. 2005. PMID: 16221072 Review.
Cited by
-
Impact of radiotherapy on circulating lymphocyte subsets in patients with esophageal cancer.Medicine (Baltimore). 2020 Sep 4;99(36):e20993. doi: 10.1097/MD.0000000000020993. Medicine (Baltimore). 2020. PMID: 32898991 Free PMC article.
-
GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.Int J Mol Sci. 2022 Jan 19;23(3):1066. doi: 10.3390/ijms23031066. Int J Mol Sci. 2022. PMID: 35162988 Free PMC article.
-
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.Cancer Immunol Immunother. 2006 Dec;55(12):1553-64. doi: 10.1007/s00262-006-0145-7. Epub 2006 Feb 21. Cancer Immunol Immunother. 2006. PMID: 16491401 Free PMC article. Clinical Trial.
-
Neuroendocrine Regulation of Tumor-Associated Immune Cells.Front Oncol. 2019 Oct 29;9:1077. doi: 10.3389/fonc.2019.01077. eCollection 2019. Front Oncol. 2019. PMID: 31737559 Free PMC article. Review.
-
Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles.J Cancer. 2020 Jan 14;11(6):1568-1583. doi: 10.7150/jca.37637. eCollection 2020. J Cancer. 2020. PMID: 32047563 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials